



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Peter Robert Baum and William Christian Fanslow III

Serial No.: 09/778,187

Filed: February 6, 2001

For:

MOLECULES DESIGNATED LDCAM

Docket No.:

2873-US

Group Art Unit No.:

Examiner: Roark, Jessica H.

MAY 3 0 2003

INFORMATION DISCLOSURE STATEMENT

**TECH CENTER 1600/2900** 

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of the references listed on the attached supplemental PTO-1449 (Modified) form for consideration by the Examiner.

Applicants, by the undersigned agent, certifies that no information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned, after making reasonable inquiry, was known to any individual designated in § 1.56(c) more than three months pursuant to 37 C.F.R. 1.97(e)(1) prior to the filing of this statement.

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge the amount of \$180 and any additional fees which may be required or credit any overpayment to Deposit Account No. 09-0089 in the name of Immunex Corporation. An original and one copy of this paper are enclosed.

Respectfully submitted,

Paul B. Tran, Ph.D. Agent for Applicants

Registration No.: 41,565 Phone: (206) 265-6293

Date: May 23, 2003

05/28/2003 MMEKONEN 00000025 090089

02 FC:1806

180.00 CH

Please send all future correspondence to:

09778187

Immunex Corporation Law Department 51 University Street Seattle, WA 98101 (206) 587-0430